A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs

26Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

This study examined the effect of ozagrel, a thromboxane A2 synthase inhibitor, on the accumulation of leucocytes and chemokine mRNA expression in lungs experimentally injured using oleic acid (OA). OA injection into guinea pigs rapidly increased thromboxane A2 generation and subsequently increased total protein concentration and the numbers of macrophages and neutrophils in bronchoalveolar lavage fluid and increased monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in the whole lung. Administration of ozagrel prevented these changes associated with OA injection. Ozagrel is a promising drug candidate for preventing acute lung injury. ©2009 The Japanese Pharmacological Society.

Author supplied keywords

Cite

CITATION STYLE

APA

Ishitsuka, Y., Moriuchi, H., Isohama, Y., Tokunaga, H., Hatamoto, K., Kurita, S., … Irie, T. (2009). A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. Journal of Pharmacological Sciences, 111(2), 211–215. https://doi.org/10.1254/jphs.09128SC

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free